Purdue Pharma LP - Strategic SWOT Analysis Review
Description
Purdue Pharma LP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
Purdue Pharma LP (Purdue) develops, manufactures, and markets pharmacologic therapies for the treatment and management of pain. The company undertakes the research, development, manufacture, and marketing of prescription medicines and over the counter (OTC) medicines and related healthcare products. Its major product categories include prescription opioids, sedatives for sleep disorders, laxatives, antiseptics, and dietary supplements. Its products offered include OxyContin, Butrans, Nalmefene HCL, Hysingla ER and Zurnai. The company also conducts clinical studies on new investigational drugs and pharmaceuticals on the market. The company operates facilities in North Carolina and New Jersey. Purdue is headquartered in Stamford, Connecticut, the US.
Purdue Pharma LP Key Recent Developments
Nov 14,2025: Bankruptcy Court Approves Purdue Pharma's Reorganization Plan
Sep 02,2025: Purdue Pharma Expands its Provision of Low-Cost Opioid Use Disorder Treatment to Correctional Facilities for Incarcerated Individuals
Jun 20,2025: Purdue Pharma Receives Court Approval of Disclosure Statement Filed in Connection with its Plan of Reorganization
Mar 19,2025: Sacklers to pay up to $7bn in Purdue Pharma’s opioid settlement plan
Reasons to Buy
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Purdue Pharma LP (Purdue) develops, manufactures, and markets pharmacologic therapies for the treatment and management of pain. The company undertakes the research, development, manufacture, and marketing of prescription medicines and over the counter (OTC) medicines and related healthcare products. Its major product categories include prescription opioids, sedatives for sleep disorders, laxatives, antiseptics, and dietary supplements. Its products offered include OxyContin, Butrans, Nalmefene HCL, Hysingla ER and Zurnai. The company also conducts clinical studies on new investigational drugs and pharmaceuticals on the market. The company operates facilities in North Carolina and New Jersey. Purdue is headquartered in Stamford, Connecticut, the US.
Purdue Pharma LP Key Recent Developments
Nov 14,2025: Bankruptcy Court Approves Purdue Pharma's Reorganization Plan
Sep 02,2025: Purdue Pharma Expands its Provision of Low-Cost Opioid Use Disorder Treatment to Correctional Facilities for Incarcerated Individuals
Jun 20,2025: Purdue Pharma Receives Court Approval of Disclosure Statement Filed in Connection with its Plan of Reorganization
Mar 19,2025: Sacklers to pay up to $7bn in Purdue Pharma’s opioid settlement plan
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Table of Contents
37 Pages
- Section 1 - About the Company
- Purdue Pharma LP - Key Facts
- Purdue Pharma LP - Key Employees
- Purdue Pharma LP - Key Employee Biographies
- Purdue Pharma LP - Major Products and Services
- Purdue Pharma LP - History
- Purdue Pharma LP - Company Statement
- Purdue Pharma LP - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Purdue Pharma LP - Business Description
- R&D Overview
- Purdue Pharma LP - Corporate Strategy
- Purdue Pharma LP - SWOT Analysis
- SWOT Analysis - Overview
- Purdue Pharma LP - Strengths
- Purdue Pharma LP - Weaknesses
- Purdue Pharma LP - Opportunities
- Purdue Pharma LP - Threats
- Purdue Pharma LP - Key Competitors
- Section 3 – Company’s Lifesciences Financial Deals and Alliances
- Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- Purdue Pharma LP, Recent Deals Summary
- Section 4 – Company’s Recent Developments
- Nov 14, 2025: Bankruptcy Court Approves Purdue Pharma's Reorganization Plan
- Sep 02, 2025: Purdue Pharma Expands its Provision of Low-Cost Opioid Use Disorder Treatment to Correctional Facilities for Incarcerated Individuals
- Jun 20, 2025: Purdue Pharma Receives Court Approval of Disclosure Statement Filed in Connection with its Plan of Reorganization
- Mar 19, 2025: Sacklers to pay up to $7bn in Purdue Pharma’s opioid settlement plan
- Mar 19, 2025: Purdue Pharma L.P. Files New Plan of Reorganization Providing for More Than $7.4 Billion in Creditor Distributions
- Jan 23, 2025: AG Campbell Helps Secure $7.4 Billion, Up To $108 Million For Massachusetts, From Purdue Pharma And The Sackler Family For Fueling The Opioid Crisis
- Section 5 – Appendix
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Purdue Pharma LP, Key Facts
- Purdue Pharma LP, Key Employees
- Purdue Pharma LP, Key Employee Biographies
- Purdue Pharma LP, Major Products and Services
- Purdue Pharma LP, History
- Purdue Pharma LP, Other Locations
- Purdue Pharma LP, Subsidiaries
- Purdue Pharma LP, Key Competitors
- Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- Purdue Pharma LP, Recent Deals Summary
- List of Figures
- Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

